NUVATION BIO’s Execs Pump Up Shares as Fast‑Track Drug Sparks Insider Buying Frenzy

Insider Activity Highlights a Strategic Shift at NUVATION BIO

On August 19, 2026, Chief Scientific Officer Gary Hattersley executed a notable buy of 100,000 Class A common shares at $1.87 each, adding to his existing holdings of 748,130 options. This purchase came after a substantial sale of 100,000 shares under a 10(b)(5)(1) plan at an average price of $7.09, and a sale of 100,000 options for 400,000 shares. The timing—just a day after the company’s Fast‑Track designation for safusidenib—suggests that Hattersley is positioning himself for the anticipated upside from the drug’s potential regulatory approval.

What the Transaction Means for Investors

The net effect is a modest increase in Hattersley’s equity stake, but the broader context is telling. NUVATION BIO has posted an 11.4 % weekly gain and a 140.6 % YTD rally, driven largely by the safusidenib news. A CEO and C‑suite buy at the low end of the current price range (near the 52‑week low of $2.83) signals confidence that the company’s valuation has room to climb. For investors, this insider optimism is a bullish cue, especially as the company’s price‑to‑earnings ratio remains negative at –16.69, indicating that earnings are still pending the success of upcoming Phase 3 data.

Hattersley’s Historical Insider Pattern

Reviewing Hattersley’s filing history shows a consistent pattern of option ownership and occasional share sales under structured plans. The 2026 February 27 filing recorded a purchase of 748,130 options at no cost, which Hattersley later exercised in August. His transactions have largely been option‑centric, with occasional market‑price share sales to diversify holdings. This behavior aligns with a long‑term view of the company’s pipeline: he prefers the upside potential of options while remaining liquid enough to sell when market conditions are favorable.

Broader Company Insider Activity

Other executives have also shown activity: CFO Philippe Sauvage bought nearly 40,000 shares in July, and several officers executed option sales in June and July. The mix of buys and sells across the leadership team underscores a healthy insider confidence in NUVATION BIO’s trajectory, even as the company navigates the regulatory and commercial challenges typical of biotech firms.

Looking Ahead

With safusidenib poised to enter pivotal Phase 3 trials, the market is watching closely. Hattersley’s recent buy, coupled with the broader insider confidence, could foreshadow a continued share price rally if the clinical data supports the Fast‑Track designation. Investors should monitor upcoming trial results, FDA feedback, and any further insider transactions to gauge whether the company’s valuation will continue to ascend or if the market will correct on the back of unmet expectations.